The Biden Cancer Initiative is a response to the lack of a cohesive, comprehensive and timely approach to cancer prevention, detection, diagnosis, research, and care.
Fueled by urgency, we stand on behalf of every patient, every family, every community having to deal with a cancer diagnosis and the complex and confusing maze they must navigate thereafter.
We are an independent nonprofit organization that builds on the White House Cancer Moonshot’s goals and grounded on Vice President Joe Biden and Dr. Jill Biden’s firm commitment to ending cancer as we know it.
“We are creating the cancer research and health care system that people think we already have.”
– Joe Biden, Chair, Biden Cancer Initiative
The Biden Cancer Initiative will develop and drive implementation of solutions to accelerate progress against cancer.
On September 21, 2018, the Biden Cancer Summit in Washington, D.C. and in more than 450 communities focused global attention on journey of cancer patients, their families, caregivers, health care professionals, and others who are in this fight every day.
One summit about cancer is not enough. To make this relevant to the concerns of patients, families, health care providers, scientists and everyone involved in this fight, we organized more than 450 Biden Cancer Community Summits on September 21st, inspiring communities to have meaningful conversations, and develop shared action plans needed to improve the cancer journey.
#cancerFIERCE is a public engagement campaign to focused on turning the fear that comes with a cancer diagnosis into FIERCE – that strength, resilience, purpose, and hope that we know is in everyone touched by cancer.
The Biden Cancer Colloquia provokes discussion and collaboration within the biotech, technology, science, and academic fields to drive innovation, technology, and breakthroughs against cancer.
The Biden Cancer Collaborative mobilizes the cancer patient and advocacy community around key priorities, promotes, and shares tried and tested approaches to addressing common problems.